Ethical use of Off-label disease-modifying therapies used in MS
The MS International Federation’s Atlas of MS showed that off-label disease-modifying therapies are used in at least 89 countries. This highlights the need for transparent evidence-based guidelines to support clinical decision-making, pharmaceutical policies and reimbursement decisions. Because there has been much debate about this, MSIF decided one of the first steps had to be a […]